The Synthetic Cannabinoid WIN 55,212-2 Can Disrupt the Golgi Apparatus Independent of Cannabinoid Receptor-1.

Joshua Lott, Emily M. Jutkiewicz, and Manojkumar A. Puthenveedu*

Department of Pharmacology, University of Michigan Medical School, Ann Arbor, MI

*Corresponding author (puthenve@umich.edu)

WIN 55,212-2 Disrupts the Golgi Apparatus

Manojkumar A. Puthenveedu
telephone/fax: 734-936-6640
Email: puthenve@umich.edu

Text pages: 18

Tables: 0

Figures: 6

References: 47

Abstract: 207

Introduction: 576

Discussion: 1037

Abbreviations

2-arachidonoylglycerol (5Z,8Z,11Z,14Z)-5,8,11,14-Eicosatetraenoic acid, 2-hydroxy-1-(hydroxymethyl)ethyl ester) – 2AG

Anandamide (N-(2-Hydroxyethyl)-5Z,8Z,11Z,14Z-eicosatetraenamide) – AEA

Brefeldin A (1,6,7,8,9,11a β ,12,13,14,14 $\alpha\alpha$ -Decahydro-1 β ,13 α -dihydroxy-6 β -methyl-4H-cyclopent(f)oxacyclotridecin-4-one) – BFA

Cannabinoid receptor-1 – CB1

Cannabinoid receptor-1 knock-out – CB1-KO

Central nervous system – CNS

G protein-coupled receptor – GPCR

JWH-018 (1-naphthalenyl(1-pentyl-1H-indol-3-yl)-methanone) –JWH

WIN 55,212-2 (R-(+)-[2,3-Dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-naphthalenylmethanone mesylate) – WIN

WIN 55,212-3 ([(3S)-2,3-dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-naphthalenyl-methanone, methanesulfonate) –WIN-3

Abstract:

The synthetic cannabinoid WIN 55,212-2 (WIN) is widely used as a pharmacological tool to study the biological activity of cannabinoid receptors. In contrast to many other cannabinoid agonists, however, WIN also causes broad effects outside of neurons, such as reducing inflammatory responses, causing cell cycle arrest, and reducing general protein expression. How exactly WIN causes these broad effects is not known. Here we show that WIN partially disrupts the Golgi apparatus at nanomolar concentrations, and fully disperses the Golgi apparatus in neuronal and non-neuronal cells at micromolar concentrations. WIN 55,212-3, the enantiomer of WIN, JWH-018, a related alkylindole, or 2-arachidonoylglycerol, an endocannabinoid, did not cause Golgi disruption, suggesting the effect was specific to the chirality of WIN. WIN treatment also perturbed the microtubule network. Importantly, WIN disrupted the Golgi in primary cortical neurons derived from mice where CB1 was genetically knocked out, indicating that the effects were independent of CB1 signaling. The Golgi dispersion could not be explained by WIN's action on Peroxisome Proliferator-Activated Receptors. Our results show that WIN can disrupt the Golgi apparatus independent of CB1 in cultured cells. These effects could contribute to the unique physiological effects that WIN exhibits in neuronal behavior, as well as its role as an antiproliferative and anti-inflammatory agent.

Significance Statement:

The synthetic cannabinoid WIN, widely used to investigate the cannabinoid system, also shows unique broader effects at cellular and organismal levels compared to endogenous cannabinoids. Our study shows that WIN can disrupt the Golgi apparatus and the microtubule network in multiple cell types, independent of cannabinoid receptors. These results could explain how WIN reduces surface levels of proteins and contributes to the unique physiological effects observed with WIN.

Introduction:

Cannabinoid ligands are versatile pharmacological agents. Cannabinoids primarily activate the Cannabinoid receptor-1 (CB1), a G protein-coupled receptor (GPCR) that plays a vital role in modulating neurotransmission in the central nervous system (CNS) and in the peripheral nerves. In the CNS, CB1's activation is part of a highly coordinated retrograde signaling mechanism (Castillo et al., 2012; Ohno-Shosaku and Kano, 2014), which suppressed neuronal depolarization as highlighted by numerous electrophysiological recordings (Kreitzer and Regehr, 2001; Ohno-Shosaku et al., 2001; Wilson and Nicoll, 2001). Cannabinoid agonists are valuable therapeutics for addressing drug addiction, neuropathic pain, epilepsy and various psychiatric disorders (Jetly et al., 2015; Mücke et al., 2018; O'Connell et al., 2017; Segura et al., 2019; Smith et al., 2015).

The synthetic cannabinoid WIN55,212-2 (WIN) is a high affinity CB1 agonist that is widely used to investigate cannabinoid physiology. WIN's increased potency compared to the endogenous cannabinoids 2-arachidonoylglycerol (2AG) and anandamide (AEA), which are partial agonists for CB1 (Pertwee, 2005), oftentimes makes it a preferred compound used to study cannabinoid pharmacology in cells and animals (Chen et al., 2021; Martini et al., 2010; Sim-Selley and Martin, 2002). However, WIN is a particularly interesting cannabinoid agonist in this regard, as it shows unique pharmacological and physiological outcomes. These outcomes could be driven by WIN's unique chemical properties, including stereoisomer specificity (Emery et al., 2013). One notable physiological difference between WIN and other cannabinoids is observed in cancer pharmacology, where WIN has been shown to cause robust anti-proliferative effects in oncogenic cells (Emery et al., 2013; Müller et al., 2017; Pellerito et al., 2014; Scuderi et al., 2011; Wasik et al., 2011). In addition, WIN has also been proposed to have anti-inflammatory and antiproliferative effects in a variety of settings (Marchalant et al., 2007;

Marchalant et al., 2008; Wang et al., 2018; Zhao et al., 2010). These broad effects have generated interest in the role of synthetic cannabinoids like WIN in physiological systems outside of the CNS.

One overarching theme that is unique to WIN's actions at the cellular level is a reduction in the surface expression and secretion of proteins. For neurotransmitter receptors and their accessory proteins, this reduction can have profound effects on neurotransmission (Blume et al., 2013; Perdikaris et al., 2018). WIN down-regulates the surface expression of CB1 and GABA_A subunits (Deshpande et al., 2011). This reduction might be partly due to a decrease in total protein expression via mRNA downregulation (Perdikaris et al., 2018; Tan and Cao, 2018). Similarly, in non-neuronal cells, WIN reduces the generation of inflammatory mediators in non-neuronal cells (Lowin et al., 2016), suggesting that the effects of WIN on surface expression and secretion of proteins could be general. However, whether WIN generally regulates protein trafficking, and whether WIN's effects on surface expression of proteins are via CB1 activation, are not fully known.

In this study, we used high-resolution fluorescence microscopy to explore the effects of WIN on components of the trafficking machinery in neuronal and non-neuronal cells. We found that WIN, but not its enantiomer WIN55,212-3, the related alkylindole JWH-018, or the endocannabinoid 2AG, partially disrupts the Golgi apparatus at nanomolar concentrations and completely disrupts the Golgi apparatus in both neuronal and non-neuronal cells at micromolar concentrations. WIN treatment disrupted the Golgi in neurons obtained from CB1 knock-out (KO) mice, suggesting that this effect is CB1-independent. Our findings provide a potential mechanism by which WIN can reduce levels of select surface proteins and produce a broad range of physiological effects independent of CB1.

Materials and Methods:

Cell Culture and Reagents

Experiments performed in HEK293 cells (American Tissue Culture Collection, Manassas, VA) were cultured in DMEM high glucose (Thermo Fisher Scientific) + 10% fetal bovine serum (FBS, GIBCO). E18 striatal neurons were obtained from BrainBits, LLC and cultured for 2 weeks following the recommended protocol. Cortical CB1-KO neurons were obtained from P0 mice and cultured for 2 weeks following the BrainBits, LLC recommended protocol. Cells in the lab are tested routinely for mycoplasma contamination. CB1 knockout mice were described in Ledent et al. (1999). SNAP-Cell[®] 647-SiR (300nM; New England Biolabs) was used to label SNAP-CB1 in HEK293 cells. Drugs used for treatment conditions were obtained and prepared as follows: 2AG was purchased from Tocris Bioscience and prepared as a 10mM stock with ethanol. WIN, GW6471 and GW9662 were purchased from Sigma-Aldrich (St. Louis, MO) and prepared as 10mM stocks with DMSO.

Experimental protocols

HEK293 cells were transfected with SNAP-CB1 and GPP130-GFP using Effectene (QIAGEN) according to the provided manufacture protocols. Stable cell lines were generated using selection with Geneticin (Invitrogen). Cell viability was assessed by labeling cells with Trypan Blue stain and manually counting the cells labeled using a counting chamber. Protein secretion was estimated by washing cells with PBS, incubating cells in PBS for 1 hour, and estimating the amount of protein in the supernatant by using a Pierce BCA Protein Assay (Thermo Fisher Scientific). Surface delivery of CB1 was estimated using a sequential labeling protocol. HEK cells expressing SNAP-CB1 were labeled with impermeable SNAP-Cell[®] 488

(300nM; New England Biolabs) to saturate the surface CB1. They were then incubated with impermeable SNAP-Cell[®] 647 (100nM; New England Biolabs) for 1 hour in the presence or absence of WIN. The ratio of 647/488 was used to measure the relative amount of new CB1 delivered to the surface.

Fixed-cell Immunofluorescence

After each drug treatment, cells were fixed with 4% paraformaldehyde (P6148; Sigma-Aldrich) for 15 minutes, and processed for immunofluorescence as described recently (Kunselman et al., 2021). After fixation, antibody labeling was performed as follows: Anti-GPP130 (1:1000; provided by Adam Linstedt, Carnegie Mellon University, Pittsburgh, PA). Anti-TGN46 (1:1000; ab50595; abcam). Anti-TGN-38 (1:1000; T9826; Sigma-Aldrich). Anti-GM130 (1:1000; PA5-95727 Thermo Fisher Scientific). Anti- α -tubulin (1:1000; ab185031; abcam). Anti-MAP2 (1:1000; ab5392; abcam). Confocal images were taken on a Nikon Eclipse Ti inverted microscope using a 20x/0.75 NA, 60x/1.49 NA or 100x/1.49 NA objective. The images were acquired with an iXon+ 897 electron-multiplying charge-coupled device camera using Andor IQ software (Andor).

Image analysis protocols

All images were analyzed via ImageJ. We generated custom ImageJ macros for standardized quantification of GPP130 and α -tubulin in HEK cells, TGN-38 in rat striatal neurons (BrainBits, LLC), and GM130 in mouse CB1-KO cortical neurons (Ledent et al., 1999). Briefly, images were thresholded using a specific value, and the area and the fluorescence of the objects identified above threshold were used for data analysis. The parameters for analysis were kept identical between the control and the experimental conditions.

Statistical Analysis

This exploratory study was designed to address the effect of WIN on membrane trafficking. Sample sizes (number of cells or fields to be analyzed), were determined before the experiment was performed, and the p-values reported are descriptive. All analysis was performed on GraphPad Prism 8, 2019. We determined before viewing the data that each group would be compared to the respective control conditions. Data were analyzed by D'Agostino-Pearson test for normal distribution. For normally distributed data, statistical significance for analysis comparing two experimental conditions was derived from unpaired t-tests, and for three or more conditions by ordinary one-way ANOVAs and multiple comparisons by a Dunnett's test. For data not normally distributed, statistical significance for analysis comparing two experimental conditions was derived from Mann Whitney tests, and for three or more conditions by Kruskal-Wallis test with multiple comparisons by a Dunn's test. All analyses are reported. For each graph, n denotes the number of cells analyzed for each condition for single-cell analyses, or the number of fields analyzed for each condition for conditions that test penetrance of phenotype. Statistical significance is denoted as follows: ns, not significant; *, $p < 0.05$; **, $p < 0.01$; ***, $p < 0.001$; ****, $p < 0.001$.

Results:

WIN Disrupts the Golgi Apparatus.

We first tested the effect of WIN in CB1-expressing HEK293 cells. HEK293 cells stably expressing SNAP-tagged CB1 were treated with 10 μ M of either WIN or 2AG for one hour, and labeled with a cell-permeable SNAP label to detect CB1. In control cells, CB1 was present on the cell surface and on intracellular compartments that roughly overlapped with the Golgi apparatus, detected by the cis-Golgi marker GPP130 (Figure 1a). This suggests that CB1 could localize to the Golgi in steady state conditions in these cells. This intracellular CB1 localization is consistent with previous reports (Grimsey et al., 2010; Leterrier et al., 2004), as is also observed for other GPCRs such as the δ -opioid receptor in neuronal cells (Shiwarski et al., 2017). This intracellular localization did not change when cells were treated with the endocannabinoid 2AG. In contrast, this intracellular pool of CB1 became more dispersed across the cytoplasm in cells treated with WIN (Figure 1A).

This finding raised the question as to whether the dispersed localization induced by WIN was due to specific redistribution of CB1, or whether this was due to general dispersal of the Golgi. To test this, we imaged the behavior of the general Golgi marker GPP130. GPP130 appeared fully dispersed across the cytoplasm upon WIN treatment, compared to the discrete staining seen in untreated cells or cells treated with 2AG (Figure 1A). To quantify dispersal of Golgi compartments, we reasoned that dispersal would result in redistribution of fluorescence over a larger area, and, correspondingly, that the fluorescence in each area will be reduced. Therefore, we measured the fraction of total cell area covered by the Golgi. In control and 2AG conditions, the Golgi covered roughly 20% of the cell's total area. In contrast, in WIN-treated cells, the Golgi covered roughly 60% of the cell's total area (Figure 1B). We next measured the average

fluorescence of the Golgi marker GPP130 in the three conditions. In WIN-treated cells, the Golgi fluorescence decreased almost three-fold compared to that of control and 2AG-treated cells (Figure 1C). This decrease roughly corresponded to the three-fold increase in area. The reciprocal changes in area and fluorescence indicate that the Golgi was dispersed in cells after WIN treatment.

We next developed an automated analysis paradigm using area and fluorescence constraints to detect Golgi dispersion in cells imaged at 20x magnification (Supplemental Figure 1; Figure 1D). Although this assay was of lower resolution and therefore lower sensitivity, this allowed us to analyze dispersion in a higher throughput and objective manner. Using this assay, we observed that WIN dispersed the Golgi at concentrations $\geq 5\mu\text{M}$ (Figure 1E). Because GPP130 is a cis-Golgi protein, we next used the trans-Golgi network (TGN) marker TGN46 to examine the effect of WIN on the TGN. We found that the TGN46 was also redistributed $\geq 5\mu\text{M}$ concentrations of WIN treatment (Figure 1F).

We performed high resolution confocal imaging to examine if WIN produced a partial effect at lower concentrations, in cells treated with concentrations of WIN ranging from 50nM to 400nM. (Figure 1G). Our results show that WIN can fragment the Golgi in concentrations as low as 50nM (Figure 1H). The Golgi fragmentation we observed was not an indirect effect of WIN changing cell viability, as a three-hour WIN [10 μM] treatment did not affect cell viability as measured by Trypan Blue (Supplemental Figure 2).

WIN, but not related alkylindoles, disrupt the Golgi Apparatus rapidly and reversibly

We next compared the time-course of WIN-mediated Golgi disruption to that of Brefeldin-A (BFA), a fungal metabolite that has been extensively used as a standard to study Golgi collapse

and reassembly. HEK293 cells expressing a GPP130-GFP were imaged live every 30 seconds for 10 minutes after treatment with 10 μ M WIN or 5 μ g/mL BFA, as described (Donaldson et al., 1990). WIN caused Golgi disruption within seven minutes of treatment, very similar to BFA (Figure 2A). To test if WIN-mediated disruption was reversible, we treated cells with WIN [10 μ M], washed out the agonist, and imaged GPP130-GFP in the cells for two hours after washout. Over this period, the dispersed Golgi fragments reassembled, and formed a discrete Golgi structure in the cell center between 90 minutes and 120 minutes after washout (Figure 2B), comparable to the kinetics of reassembly after BFA (Langhans et al., 2007).

To explore the region of WIN that was involved in Golgi disruption, we tested two other synthetic cannabinoids that shared chemical properties with WIN - the clinically relevant naphthoylindole compound, JWH-018, and the enantiomer of WIN, WIN55,212-3, which differs in chirality at the morpholine group. We imaged HEK293 cells expressing a GPP130-GFP every 30 seconds for 10 minutes after JWH [10 μ M] and WIN-3 [10 μ M] treatment. Neither compound caused Golgi disruption, suggesting that the disruption is specific to the stereochemical structure of WIN (Figure 2C).

WIN Disrupts Microtubules.

Because Golgi structure and an intact microtubule architecture in the cell are highly interdependent, we investigated whether WIN disrupted the microtubule structure in addition to dispersing the Golgi. In HEK293 cells treated with WIN [10 μ M] for one hour, the characteristic filament network of the microtubule cytoskeleton was visually disrupted at a similar timepoint as Golgi dispersion (Figure 3A). We next attempted to quantify this microtubule disruption using image analysis. The intricacy of microtubule filaments added a substantial degree of difficulty

when processing 2D images. Therefore, we enhanced the network by using ImageJ for standardized tubule segmentation across all sample images, as previously described (Kalkofen et al., 2015). We then measured the fluorescence intensity of the defined network and found a significant decrease in WIN-treated cells compared to control conditions (Figure 3B). Our findings are further supported by a strong correlation between Golgi and microtubule disruption. We found that microtubule fluorescence decreased as Golgi fluorescence decreased (Figure 3C), which represents a coinciding disruption of both cellular structures after WIN treatment.

WIN Disrupts Golgi in Primary Cultured Neurons.

To test whether WIN could disrupt Golgi in multiple cell types including physiologically relevant neurons, we treated embryonic striatal neurons with WIN and assessed Golgi disruption. Consistent with our results in HEK293 cells, we saw robust dispersal of the Golgi in neurons treated with saturating concentrations, 10 μ M, of WIN (Figure 4A). When Golgi dispersal was quantified by measuring area and fluorescence, the Golgi spread across a larger surface area after WIN [10 μ M] treatment (Figure 4B), and the detected TGN38 fluorescence decreased as the surface area increases (Figure 4C). A characteristic feature of the mammalian Golgi is that it is located at the microtubule organizing center in the center of the cell body. Therefore, as an orthogonal and higher sensitivity method to quantify neuronal Golgi disruption and localization, we measured the distribution of fluorescence intensity as a function of the distance from the cell center, by generating radial profiles of antibody fluorescence across a projected 2D field (Figure 4D). The workflow for generating radial profile plots is provided in Supplemental Figure 3. In control and WIN [1 μ M] treatment conditions, the Golgi fluorescence showed a clear peak at shorter radial lengths, indicating that Golgi fluorescence was concentrated near the cell center,

consistent with an intact Golgi apparatus (Figure 4E). When neurons were treated with WIN [5 μ M], the Golgi fluorescence was more evenly dispersed across all radial lengths of the neuronal cell body (Figure 4E). Interestingly, the fluorescence was overall lower across all radii in WIN-treated neurons, as observed by lower total fluorescence estimated as areas under the curve for radial plot values (Figure 4F). This difference suggests that the Golgi is redistributed beyond the neuronal cell body into dendrites, as the estimates of radial profiles are restricted to the neuronal body. These results show that WIN causes Golgi disruption in multiple cell types including physiologically relevant striatal neurons.

As a control, we treated embryonic striatal neurons with 2AG and measured Golgi stability using a similar approach as above. No significant differences in Golgi area (Figure 4F) or fluorescence (Figure 4G) were detected. Additionally, in both control and 2AG treatment conditions, the Golgi signal is concentrated near the nucleus, as measured through our radial profile quantification approach (Figure 4H). These results indicate that WIN, but not 2AG, disrupts the Golgi apparatus in neurons.

Golgi Disruption by WIN is independent of CB1.

In both HEK293 cells and embryonic striatal neurons, WIN treatment at ~ 5 μ M concentrations resulted in Golgi disruption despite variations in cellular CB1 expression. This raised the possibility that the effects of WIN on the Golgi are independent of CB1 receptor expression. To directly test this, we measured Golgi disruption by WIN in cortical neurons cultured from mice in which CB1 was genetically knocked out (CB1-KO) (Ledent et al., 1999) to determine if CB1 was required for WIN-mediated organelle disruption. Neuronal identity of cultured cells was confirmed using the neuronal marker MAP2. Upon treatment with WIN

[10 μ M], we observed that GM130, a cis-Golgi marker, was dispersed in CB1-KO neurons, as well as neurons cultured from wild-type littermates (Figure 5A). To quantify Golgi disruption in CB1-KO neurons we measured the fraction of total cell area covered by GM130 and the fluorescence intensity of detected antibody signal as in Fig 1. Golgi coverage in the neuronal cell body significantly increased when the Golgi was disrupted (Figure 5B), and the fluorescence intensity of detected antibody signal decreased as area increased (Figure 5C). Both these were comparable to the effects we observed in HEK293 cells. Golgi dispersal was also evident when radial profile plots were used to quantify dispersion. The radial plots show a fluorescence peak at shorter radial lengths in control neurons, but not neurons treated with WIN [10 μ M] for 20 minutes or one hour (Figure 5D). Together, our results show that WIN can cause Golgi dispersion in multiple cell types, independent of CB1 expression.

Golgi Disruption is PPAR-independent.

Because WIN-mediated Golgi dispersal was independent of the primary receptor CB1, we examined whether WIN acted via its main other known effectors - the nuclear proliferator-activated receptors alpha and gamma (PPAR α and PPAR γ) (O'Sullivan, 2016). To test if PPAR was required for Golgi disruption, we co-treated HEK293 cells with WIN and either a PPAR α inhibitor (GW6471 [10 μ M]) or a PPAR γ inhibitor (GW9662 [10 μ M]) for one hour. Inhibition of neither PPAR α or PPAR γ blocked Golgi disruption completely when HEK293 cells were treated with WIN, suggesting that PPAR activation was not required for WIN-mediated Golgi disruption. However, GW9662 showed a partial protective effect in comparison to control when HEK293 cells were treated with WIN [5 μ M] (Figure 6A). To assess the penetrance of the phenotype of Golgi disruption, we determined the fraction of fields in which the majority

(>50%) of HEK293 cells within the field displayed Golgi disruption after WIN treatment. The Golgi was intact for all fields of HEK293 cells in control conditions. In contrast, Golgi disruption was observed upon treatment with WIN [5 μ M] and WIN [10 μ M] in all cells, irrespective of whether PPAR was inhibited (Figure 6B). The quantitation confirmed that GW9662 [10 μ M] produced a partial protective effect in HEK293 cells treated with WIN [5 μ M], suggesting that PPAR γ , although not required, might play a contributory role in WIN-mediated disruption of the Golgi.

Discussion:

In this study, we show that WIN can disrupt the Golgi apparatus across multiple cell types, including primary neurons, with partial disruptions starting at nanomolar concentrations and complete disruption at micromolar concentrations. These general effects of WIN are independent of CB1 expression and are effected through an as-yet undiscovered pathway that could be partially regulated by PPARs.

Our results provide a new context to the use of WIN in experimental and behavioral contexts. The divergent effects observed with WIN have often been considered to be due to the unique ways that it might activate CB1 compared to endocannabinoids. This could certainly be true, and part of WIN's unique effects could be explained by differential activation of CB1. For example, WIN exhibits weakened β -arrestin signaling compared to 2AG (Flores-Otero et al., 2014). However, WIN can also elicit CB1-independent effects. WIN can halt proliferation in oncogenic cells (Emery et al., 2013; Müller et al., 2017; Pellerito et al., 2014) independent of CB1 signaling (Scuderi et al., 2011). Additionally, WIN shows anti-inflammatory and anti-nociceptive properties that have also been identified as CB1-independent (Price et al., 2004). One point of consideration is that WIN caused complete Golgi disruption at micromolar concentrations of WIN. However, even at these concentrations, the effect we observe is still specific to WIN, as similar concentrations of JWH-018 nor WIN55,212-3 did not cause Golgi disruption. Interestingly, WIN-mediated downregulation of the expression of proteins involved in cell growth and survival was also observed only at micromolar concentrations of WIN (Sreevalsan and Safe, 2013) similar to concentrations that can completely disrupt the Golgi apparatus as we report in this study.

WIN could, however, affect Golgi function even at nanomolar concentrations, even without causing complete collapse of the Golgi. In this context, one clear strength of our quantitative imaging approach is that we can detect small changes in the Golgi architecture, which might be missed by traditional biochemical approaches, with high sensitivity. Because the Golgi apparatus is a processing station for many post-translational modifications, including glycosylation, small changes in the Golgi architecture can cause differences in protein processing without changing trafficking rates overall (Puthenveedu et al., 2006). To the best of our knowledge, the exact concentrations of WIN in different brain regions after administration in mice are not known. In mice injected with 2.5 mg/kg of the synthetic cannabinoid JWH-018 i.p., the serum concentration can reach 250nM (Malyshevskaya et al., 2017). Our results suggest that WIN causes partial fragmentation of the Golgi starting at 50nM (Figure 1), even without large changes in protein secretion (Supplemental Figure 2B). The disruption of the Golgi and associated changes in processing of select proteins could contribute to the wide-ranging physiological effects of WIN.

Our results suggest that the disruption of the Golgi apparatus is specific to the stereochemistry of WIN. WIN belongs to the aminoalkylindole family of cannabinoids. Some alykylindoles can destabilize microtubules and promote cell death through direct microtubule binding (Cherry et al., 2016). Moieties linked to the nitrogen of pyrrole rings are the structural determinants of alykylindole-microtubule interactions, where bulkier moieties prevent microtubule binding (Fung et al., 2017). However, it is unlikely that the effect of WIN on the Golgi is through microtubule disruption by alkylindoles. First, the interplay between microtubules and cytoskeleton is bidirectional, as microtubules are required for a discrete Golgi ribbon to exist at the cell center, and as the Golgi can nucleate microtubules (Wu and Akhmanova, 2017). Second,

the dispersal and kinetics of Golgi disruption we observe match BFA, and is faster than reported for microtubule disruption. Third, neither JWH-018 nor WIN55,212-3, which share the alkylindole group, caused Golgi disruption. Rather, the chirality of the morpholine group seems to be important for WIN, as WIN55,212-3 does not disrupt the Golgi. The exact mechanism by which the morpholine group disrupts the Golgi apparatus is not known. It is possible that this group binds to an unknown effector. WIN also contains an oxazine group which has been suggested to have anti-tumor properties, and it is possible that the morpholine group might sterically control the interactions of the oxazine group with its effectors.

Our results indicate that Golgi disruption does not require CB1 activation, as we observed similar effects in HEK293 cells not expressing exogenous CB1, and in primary cells derived from CB1 knockout mice. One potential CB1-independent target of WIN is the PPAR family of nuclear receptors. WIN can activate PPAR α and PPAR γ (O'Sullivan, 2016) independent of CB1. Both PPARs can regulate lipid metabolism and could contribute to disruption of the Golgi apparatus. However, our results suggest that the effect of WINs cannot be explained fully by activation of PPARs. First, WIN disrupts the Golgi at relatively fast time scales, which makes it unlikely that a transcriptional regulatory mechanism is the primary mediator. Second, blocking PPAR activation was not sufficient to block Golgi disruption (Figure 6). PPAR γ inhibition caused a partial reduction of WIN-mediated disruption of the Golgi. Interestingly, PPAR γ inhibition on its own can down-regulate tubulin expression and inhibit cell growth (Schaefer, 2007), but the timescale required to observed downstream effects of nuclear receptors is much longer than what is sufficient for observing WIN's effect on cellular structures. WIN could target one of many proteins that have been identified as being critical for maintaining the integrity of the Golgi apparatus. These include trafficking proteins such as the coatamer protein I complex

(COPI), which is disrupted by the fungal metabolite BFA (Donaldson et al., 1990; Orci et al., 1991). However, unlike BFA, which preferentially disrupts the stacked Golgi, WIN also disrupts the trans-Golgi network as marked by TGN38 at micromolar concentrations. Future studies that identify a target for WIN will provide us with a better understanding of how WIN regulates Golgi structure, and might provide insights into the regulation of Golgi structure and trafficking in general.

Irrespective of the mechanism, our results highlight a broad effect of WIN on the Golgi apparatus that is likely to confound interpretations of its effects on cannabinoid pharmacology. These effects could contribute to WIN's role as an antiproliferative and anti-inflammatory agent by disrupting a key organelle that is central to membrane trafficking and protein processing. This study therefore generates new considerations to interpret the unique physiological effects of WIN compared to other cannabinoid agonists.

Acknowledgements:

We thank Taylor Craig and Dr. Kevin Jones for assistance with preparing neuronal cultures derived from CB1-KO mice. We thank Dr. Stephanie Crilly and Dr. Zara Weinberg for valuable discussions that helped advance this study. We sincerely thank Dr. Kenneth Mackie (Indiana University at Bloomington) for providing the mice and parent CB1 constructs, and Dr. Adam Linstedt (Carnegie Mellon University) for providing essential reagents. JL was supported by National Institutes of Health [T32-GM007767] and MAP by National Institutes of Health National Institute for General Medical Sciences [Grant GM117425] and by the National Science Foundation [Grant 1935926].

Authorship contributions:

Participated in research design: Lott, Jutkiewicz, and Puthenveedu

Conducted experiments: Lott

Contributed new reagents or analytic tools: Lott, Jutkiewicz, and Puthenveedu

Performed data analysis: Lott

Wrote or contributed to the writing of the manuscript: Lott and Puthenveedu

References:

- Blume, L. C., Bass, C. E., Childers, S. R., Dalton, G. D., Roberts, D. C. S., Richardson, J. M., Xiao, R., Selley, D. E., and Howlett, A. C. (2013). Striatal CB1 and D2 receptors regulate expression of each other, CRIP1A and delta opioid systems. *Journal of Neurochemistry*, 124(6), 808–820.
- Castillo, P., Younts, T., Chávez, A., and Hashimotodani, Y. (2012). Endocannabinoid Signaling and Synaptic Function. *Neuron*, 76(1), 70–81.
- Chen, J., Hasanein, P., Komaki, A., and Yari, S. (2021). Effects of GABAA receptors in nucleus cuneiformis on the cannabinoid antinociception using the formalin test. *Psychopharmacology*, 238(6), 1657–1669.
- Cherry, A. E., Haas, B. R., Naydenov, A. V., Fung, S., Xu, C., Swinney, K., Wagenbach, M., Freeling, J., Canton, D. A., Coy, J., Horne, E. A., Rickman, B., Vicente, J. J., Scott, J. D., Ho, R. J., Liggitt, D., Wordeman, L., & Stella, N. (2016). ST-11: A New Brain-Penetrant Microtubule-Destabilizing Agent with Therapeutic Potential for Glioblastoma Multiforme. *Molecular Cancer Therapeutics*, 15(9), 2018–2029.
- Deshpande, L. S., Blair, R. E., and DeLorenzo, R. J. (2011). Prolonged cannabinoid exposure alters GABAA receptor mediated synaptic function in cultured hippocampal neurons. *Experimental Neurology*, 229(2), 264–273.
- Donaldson, J. G., Lippincott-Schwartz, J., Bloom, G. S., Kreis, T. E., and Klausner, R. D. (1990). Dissociation of a 110-kD peripheral membrane protein from the Golgi apparatus is an early event in brefeldin A action. *Journal of Cell Biology*, 111(6), 2295–2306.
- Emery, S. M., Alotaibi, M. R., Tao, Q., Selley, D. E., Lichtman, A. H., and Gewirtz, D. A. (2013). Combined Antiproliferative Effects of the Aminoalkylindole WIN55,212-2 and Radiation in Breast Cancer Cells. *Journal of Pharmacology and Experimental Therapeutics*, 348(2), 293–302.

- Flores-Otero, J., Ahn, K. H., Delgado-Peraza, F., Mackie, K., Kendall, D. A., and Yudowski, G. A. (2014). Ligand-specific endocytic dwell times control functional selectivity of the cannabinoid receptor 1. *Nature Communications*, 5, 4589.
- Fung, S., Xu, C., Hamel, E., Wager-Miller, J. B., Woodruff, G., Miller, A., Sanford, C., Mackie, K., & Stella, N. (2017). Novel indole-based compounds that differentiate alkylindole-sensitive receptors from cannabinoid receptors and microtubules: Characterization of their activity on glioma cell migration. *Pharmacological Research*, 115, 233–241.
- Grimsey, N. L., Graham, E. S., Dragunow, M., and Glass, M. (2010). Cannabinoid Receptor 1 trafficking and the role of the intracellular pool: Implications for therapeutics. *Biochemical Pharmacology*, 80(7), 1050–1062.
- Jetly, R., Heber, A., Fraser, G., and Boisvert, D. (2015). The efficacy of nabilone, a synthetic cannabinoid, in the treatment of PTSD-associated nightmares: A preliminary randomized, double-blind, placebo-controlled cross-over design study. *Psychoneuroendocrinology*, 51, 585–588.
- Kalkofen, D. N., de Figueiredo, P., and Brown, W. J. (2015). Methods for analyzing the role of phospholipase A2 enzymes in endosome membrane tubule formation. *Sorting and Recycling Endosomes*, 157–180.
- Kreitzer, A. C., and Regehr, W. G. (2001). Retrograde Inhibition of Presynaptic Calcium Influx by Endogenous Cannabinoids at Excitatory Synapses onto Purkinje Cells. *Neuron*, 29(3), 717–727.
- Kunselman, J. M., Gupta, A., Gomes, I., Devi, L. A., & Puthenveedu, M. A. (2021). Compartment-specific opioid receptor signaling is selectively modulated by different dynorphin peptides. *ELife*, 10.
- Langhans, M., Hawes, C., Hillmer, S., Hummel, E., & Robinson, D. G. (2007). Golgi Regeneration after Brefeldin A Treatment in BY-2 Cells Entails Stack Enlargement and Cisternal Growth followed by Division. *Plant Physiology*, 145(2), 527–538.

- Ledent, C., Valverde, O., Cossu, G., Petitet, F., Aubert, J., Beslot, F., Böhme, G. A., Imperato, A., Pedrazzini, T., Roques, B. P., Vassart, G., Fratta, W., and Parmentier, M. (1999). Unresponsiveness to Cannabinoids and Reduced Addictive Effects of Opiates in CB1 Receptor Knockout Mice. *Science*, 283(5400), 401–404.
- Leterrier, C., Bonnard, D., Carrel, D., Rossier, J., and Lenkei, Z. (2004). Constitutive Endocytic Cycle of the CB1 Cannabinoid Receptor. *Journal of Biological Chemistry*, 279(34), 36013–36021.
- Lowin, T., Pongratz, G., and Straub, R. H. (2016). The synthetic cannabinoid WIN55,212-2 mesylate decreases the production of inflammatory mediators in rheumatoid arthritis synovial fibroblasts by activating CB2, TRPV1, TRPA1 and yet unidentified receptor targets. *Journal of Inflammation*, 13(1), 15 (2016).
- Malyshevskaya, O., Aritake, K., Kaushik, M. K., Uchiyama, N., Cherasse, Y., Kikura-Hanajiri, R., & Urade, Y. (2017). Natural (Δ^9 -THC) and synthetic (JWH-018) cannabinoids induce seizures by acting through the cannabinoid CB1 receptor. *Scientific Reports*, 7(1).
- Marchalant, Y., Cerbai, F., Brothers, H. M., and Wenk, G. L. (2008). Cannabinoid receptor stimulation is anti-inflammatory and improves memory in old rats. *Neurobiology of Aging*, 29(12), 1894–1901.
- Marchalant, Y., Rosi, S., and Wenk, G. (2007). Anti-inflammatory property of the cannabinoid agonist WIN-55212-2 in a rodent model of chronic brain inflammation. *Neuroscience*, 144(4), 1516–1522.
- Martini, L., Thompson, D., Kharazia, V., and Whistler, J. L. (2010). Differential Regulation of Behavioral Tolerance to WIN55,212-2 by GASPI1. *Neuropsychopharmacology*, 35(6), 1363–1373.
- Mücke, M., Phillips, T., Radbruch, L., Petzke, F., and Häuser, W. (2018). Cannabis-based medicines for chronic neuropathic pain in adults. *Cochrane Database of Systematic Reviews*, 3 (3), CD012182.
- Müller, L., Radtke, A., Decker, J., Koch, M., and Belge, G. (2017). The Synthetic Cannabinoid WIN 55,212-2 Elicits Death in Human Cancer Cell Lines. *Anticancer Research*, 37(11), 6341–6345.

- O'Connell, B. K., Gloss, D., and Devinsky, O. (2017). Cannabinoids in treatment-resistant epilepsy: A review. *Epilepsy and Behavior*, 70, 341–348.
- Ohno-Shosaku, T., and Kano, M. (2014). Endocannabinoid-mediated retrograde modulation of synaptic transmission. *Current Opinion in Neurobiology*, 29, 1–8.
- Ohno-Shosaku, T., Maejima, T., and Kano, M. (2001). Endogenous Cannabinoids Mediate Retrograde Signals from Depolarized Postsynaptic Neurons to Presynaptic Terminals. *Neuron*, 29(3), 729–738.
- Orci, L., Tagaya, M., Amherdt, M., Perrelet, A., Donaldson, J. G., Lippincott-Schwartz, J., Klausner, R. D., and Rothman, J. E. (1991). Brefeldin A, a drug that blocks secretion, prevents the assembly of non-clathrin-coated buds on Golgi cisternae. *Cell*, 64(6), 1183–1195.
- O'Sullivan, S. E. (2016). An update on PPAR activation by cannabinoids. *British Journal of Pharmacology*, 173(12), 1899–1910.
- Pellerito, O., Notaro, A., Sabella, S., De Blasio, A., Vento, R., Calvaruso, G., and Giuliano, M. (2014). WIN induces apoptotic cell death in human colon cancer cells through a block of autophagic flux dependent on PPAR γ down-regulation. *Apoptosis*, 1029–1042.
- Perdikaris, P., Tsarouchi, M., Fanarioti, E., Natsaridis, E., Mitsacos, A., and Giompres, P. (2018). Long lasting effects of chronic WIN55,212-2 treatment on mesostriatal dopaminergic and cannabinoid systems in the rat brain. *Neuropharmacology*, 129, 1–15.
- Pertwee, R. G. (2005). Pharmacological Actions of Cannabinoids. *Handbook of Experimental Pharmacology*, 1–51.
- Price, T. J., Patwardhan, A., Akopian, A. N., Hargreaves, K. M., and Flores, C. M. (2004). Cannabinoid receptor-independent actions of the aminoalkylindole WIN 55,212-2 on trigeminal sensory neurons. *British Journal of Pharmacology*, 142(2), 257–266.

- Roman-Vendrell, C., Yu, Y. J., and Yudowski, G. A. (2012). Fast Modulation of μ -Opioid Receptor (MOR) Recycling Is Mediated by Receptor Agonists. *Journal of Biological Chemistry*, 287(18), 14782–14791.
- Schaefer, K. L. (2007). PPAR- γ inhibitors as novel tubulin-targeting agents. *Expert Opinion on Investigational Drugs*, 16(7), 923–926.
- Scuderi, M. R., Cantarella, G., Scollo, M., Lempereur, L., Palumbo, M., Saccani-Jotti, G., and Bernardini, R. (2011). The antimitogenic effect of the cannabinoid receptor agonist WIN55212-2 on human melanoma cells is mediated by the membrane lipid raft. *Cancer Letters*, 310(2), 240–249.
- Segura, L. E., Mauro, C. M., Levy, N. S., Khauli, N., Philbin, M. M., Mauro, P. M., and Martins, S. S. (2019). Association of US Medical Marijuana Laws With Nonmedical Prescription Opioid Use and Prescription Opioid Use Disorder. *JAMA Network Open*, 2(7), e197216.
- Shiwarski, D. J., Darr, M., Telmer, C. A., Bruchez, M. P., and Puthenveedu, M. A. (2017). PI3K class II α regulates δ -opioid receptor export from the trans-Golgi network. *Molecular Biology of the Cell*, 28(16), 2202–2219.
- Sim-Selley, L. J., and Martin, B. R. (2002). Effect of Chronic Administration of R-(+)-[2,3-Dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone Mesylate (WIN55,212-2) or Δ^9 -Tetrahydrocannabinol on Cannabinoid Receptor Adaptation in Mice. *Journal of Pharmacology and Experimental Therapeutics*, 303(1), 36–44.
- Smith, L. A., Azariah, F., Lavender, V. T., Stoner, N. S., and Bettiol, S. (2015). Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy. *Cochrane Database of Systematic Reviews*, 11 (2015), Article CD009464.

- Sreevalsan, S., and Safe, S. (2013). The Cannabinoid WIN 55,212-2 Decreases Specificity Protein Transcription Factors and the Oncogenic Cap Protein eIF4E in Colon Cancer Cells. *Molecular Cancer Therapeutics*, 12(11), 2483–2493.
- Tan, R., and Cao, L. (2018). Cannabinoid WIN-55,212-2 mesylate inhibits tumor necrosis factor- α -induced expression of nitric oxide synthase in dorsal root ganglion neurons. *International Journal of Molecular Medicine*, 919–925.
- Wang, D. P., Yin, H., Kang, K., Lin, Q., Su, S. H., and Hai, J. (2018). The potential protective effects of cannabinoid receptor agonist WIN55,212-2 on cognitive dysfunction is associated with the suppression of autophagy and inflammation in an experimental model of vascular dementia. *Psychiatry Research*, 267, 281–288.
- Wasik, A. M., Almestrand, S., Wang, X., Hultenby, K., Dackland, L., Andersson, P., Kimby, E., Christensson, B., and Sander, B. (2011). WIN55,212-2 induces cytoplasmic vacuolation in apoptosis-resistant MCL cells. *Cell Death and Disease*, 2(11), e225.
- Wilson, R. I., and Nicoll, R. A. (2001). Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses. *Nature*, 410(6828), 588–592.
- Wu, J., and Akhmanova, A. (2017). Microtubule-Organizing Centers. *Annual Review of Cell and Developmental Biology*, 33(1), 51–75.
- Zhao, Y., Liu, Y., Zhang, W., Xue, J., Wu, Y. Z., Xu, W., Liang, X., Chen, T., Kishimoto, C., and Yuan, Z. (2010). WIN55212-2 ameliorates atherosclerosis associated with suppression of pro-inflammatory responses in ApoE-knockout mice. *European Journal of Pharmacology*, 649(1–3), 285–292.

Footnotes:

Financial Disclosure

This work was supported by the National Institutes of Health National Institute for General Medical Sciences [Grant GM117425 and T32-GM007767] and by the National Science Foundation [Grant 1935926]. No author has an actual or perceived conflict of interest with the contents of this article.

Figure Legends:

Figure 1. WIN disrupts the Golgi apparatus. (A) HEK293 cells imaged with confocal microscopy showing SNAP-CB1 and GPP130 labeling after one-hour drug treatment conditions. The Golgi is intact in control and 2AG [10μM] conditions, while GPP130 labeling shows a robust dispersal phenotype for cells in the WIN [10μM] condition. Similarly, we observe a dramatic redistribution of intracellular CB1 after WIN treatment, which we did not observed with 2AG (yellow arrows). Scale bar = 5μm. (B) GPP130 labeling covers a larger surface area after WIN treatment as the Golgi is dispersed throughout the cell, (C) and the fluorescence intensity of GPP130 correspondingly decreases as the antibody label becomes less concentrated within the defined Golgi area. (**, $p < 0.01$; ***, $p < 0.001$; ****, $p < 0.0001$; $n \geq 9$). (D) Confocal images shown at 20x magnification used for high-throughput analysis of Golgi disruption. As previously shown, Golgi dispersal is observed after one hour of WIN treatment, and the mask generated from antibody labeling was used to identify Golgi object as defined by pre-determined area and fluorescence constraints. Scale bar = 10μm. Fewer objects were detected in [5μM] and [10μM] treatment conditions for both (E) cis-Golgi compartments and (F) trans-Golgi compartments. Circles represent biological replicate means (ns, not significant; $n = 3$ averaged biological replicates). (G) Representative confocal images showing GPP130 labeling and 3D object identification. Using our analysis paradigms, when the Golgi is intact only one 3D object is detected (*white*), and when the Golgi is fragmented multiple 3D objects are detected. In this example, 2 objects are detected (*white and yellow*). Scale bar = 2.5μm. (H) Golgi fragmentation represented as a percentage of fragmented Golgi detected out of the total number of Golgi, shows that one-hour WIN treatment at nanomolar concentrations causes Golgi fragmentation, but not complete disruption.

Figure 2. WIN-mediated Golgi disruption is comparable to BFA. (A) Live-cell imaging of HEK293 cells transfected with GPP130-GFP. BFA and WIN disrupt the Golgi at roughly similar time scales. (B) Live-cell GPP130-GFP imaging shows that the Golgi partially reassembled within 2 hours of washout after 15 minutes of WIN [10 μ M] treatment. (C) The synthetic cannabinoids JWH [10 μ M] and WIN-3 [10 μ M] do not cause Golgi disruption at similar time scales. Scale bar = 2.5 μ m in all images.

Figure 3. WIN disrupts microtubule structure. (A) HEK293 cells imaged with confocal microscopy showing SNAP-CB1 and α -tubulin labeling after one-hour drug treatment conditions. As shown in Fig. 1, we observe a dramatic redistribution of intracellular SNAP-CB1 after WIN [10 μ M] treatment. Changes in microtubule organization are also observed, where the tubular network is less defined after WIN [10 μ M] treatment. α -tubulin labeling was used to generate a microtubule mask to quantify structural differences between treatment conditions. Scale bar = 5 μ m. (B) The fluorescence intensity of α -tubulin labeling is significantly decreased after WIN treatment. (**, $p < 0.01$; $n = 17$ for control and 20 for WIN). (C) Scatter plot showing the matched fluorescence intensity of α -tubulin and GPP130 values. Two distinct populations are observed, where circles in the control condition (white) have higher microtubule and Golgi fluorescence values than circles in the WIN [10 μ M] condition (blue).

Figure 4. WIN disrupts Golgi in primary cultured neurons. (A) Striatal neurons imaged with confocal microscopy and labeled to detect TGN38 after one-hour control and WIN treatment. As

observed in HEK293 cells, Golgi is dispersed in WIN [10 μ M] treated neurons, but not in control neurons. Scale bar = 2.5 μ m. By thresholding the TGN38 signal, we quantified differences in area coverage and average fluorescence. **(B)** TGN38 labeling covers a larger surface area after WIN [10 μ M] treatment, and **(C)** the subsequent fluorescence intensity of TGN38 signal is significantly decreased (**, $p < 0.01$; ****, $p < 0.0001$; $n \geq 12$). **(D)** Schematic depicting Golgi dispersal in neurons and the radial profile quantification approach used to measure TGN38 fluorescence. Fluorescence intensity is concentrated at shorter radial lengths (top panel) when the Golgi is intact, whereas in conditions where the Golgi is disrupted (bottom panel) the fluorescence intensity becomes more evenly distributed across all radial positions. **(E)** Radial plots showing TGN38 fluorescence across radial position at varying concentrations of WIN treatment. Control and WIN [1 μ M] treated neurons show peaks in fluorescence intensity at shorter radial lengths, while WIN [5 μ M] treated neurons do not show this robust peak in fluorescence. Error bars represent mean $\pm$ 95% CI ($n \geq 9$). **(F)** TGN38 labeling does not cover a larger surface area after 2AG treatment, and **(G)** the subsequent fluorescence intensity of TGN38 signal is not significantly decreased (ns, not significant; $n \geq 9$). **(H)** This is recapitulated with our radial plots where control and 2AG treatment conditions both show peaks in fluorescence intensity at shorter radial lengths. Error bars represent mean $\pm$ 95% CI ($n \geq 8$).

Figure 5. WIN-mediated Golgi disruption is CB1-independent. **(A)** Cortical neurons of CB1-KO mice and wild-type littermates imaged with confocal microscopy. The Golgi is identified with the cisternal-Golgi antibody, GM130, and neurons are identified with MAP2. As shown in HEK293 cells, the Golgi is intact for neurons in the control group, while GM130 labeling shows a dispersal phenotype for neurons in the WIN [10 μ M] condition. Scale bar = 2.5 μ m. **(B)** GM130

labeling covers a larger surface area after WIN treatment, and (C) the subsequent fluorescence intensity of GM130 is significantly decreased (*, $p < 0.05$; $n \geq 9$). (D) Radial plots showing GM130 fluorescence across radial position at varying incubation times of WIN [10 μ M] treatment. Neurons in the control group show peaks in fluorescence intensity at shorter radial positions, while neurons treated with WIN [10 μ M] for 20 minutes and one hour do not show this peak. Error bars represent mean $\pm$ 95% CI ($n \geq 10$).

Figure 6. WIN-mediated Golgi disruption does not require PPAR activity. (A) HEK293 cells imaged with confocal microscopy showing GPP130 labeling after one-hour treatment conditions. The Golgi is intact in control, GW6471 [10 μ M] and GW9662 [10 μ M] conditions, while GPP130 labeling shows a robust dispersal phenotype after WIN treatment at both [5 μ M] and [10 μ M]. Although co-treatment with WIN [5 μ M] and GW9662 [10 μ M] collapses the Golgi apparatus, the phenotype is less pronounced than what is observed after treatment with WIN alone. Scale bar = 5 μ m. (B) Stacked bar graph representation of Golgi stability as a percentage of fields exhibiting intact cis-Golgi compartments ($n = 30$ for each).

A) Control 2AG [10μM] WIN [10μM]

SNAP-CB1

GPP130

B) Golgi Area

GPP130 Area / Cell Area

Control 2AG [10μM] WIN [10μM]

C) Golgi Signal

GPP130 Fluorescence (A.U.)

Control 2AG [10μM] WIN [10μM]

D) Control WIN [10μM]

GPP130

Golgi Mask

E) Golgi Stability

of GPP130 Objects/Field

WIN [0nM] WIN [1μM] WIN [5μM] WIN [10μM]

F) Golgi Stability

TGN46 Objects/Field

WIN [0nM] WIN [1μM] WIN [5μM] WIN [10μM]

G) Intact Fragmented

GPP130

3D Object(s)

H) # of Fragmented Golgi # of Intact Golgi

[0nM] [50nM] [100nM] [200nM] [400nM]

0% 10% 17.6% 26.3% 22.7%

Total=21 Total=20 Total=17 Total=19 Total=22

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 26, 2023

Figure 2

Figure 3

Figure 4

Figure 5

A)

B)

C)

D)

Figure 6

A)

B)